Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2331 to 2340 of 2680 total matches.
In Brief: Auvi-Q Epinephrine Auto-Injector for Infants and Toddlers
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
strengths of Auvi-Q are
priced the same.
1. Drugs for allergic disorders. Med Lett Drugs Ther 2017; 59:71 ...
The FDA has approved a lower-dose epinephrine auto-injector (Auvi-Q 0.1 mg – Kaléo) for emergency treatment of anaphylaxis in children weighing 7.5-15 kg (16.5-33 lbs). It is the first epinephrine auto-injector to be approved for use in infants and toddlers weighing less than 15 kg. Previously, Auvi-Q and other epinephrine auto-injectors were only available in 0.15- and 0.3-mg strengths for patients weighing 15-30 kg or ≥30 kg, respectively.The recommended dose of epinephrine for intramuscular (IM) or subcutaneous (SC) administration is 0.01 mg/kg. None of the previously available...
Expanded Table: Statins (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
The Medical Letter ® Vol. 61 (1581) September 23, 2019
Table 1. Statins
Average LDL-C
Drug Some ...
View the Expanded Table: Statins
In Brief: Abemaciclib (Verzenio) for Early Breast Cancer
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
twice daily taken
in combination with tamoxifen or an aromatase
inhibitor. The drug should be taken ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
abemaciclib (Verzenio – Lilly), which was approved
by the FDA in 2017 for treatment of hormone receptor
(HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative advanced or metastatic
breast cancer, has now been approved for use in
combination with endocrine therapy (tamoxifen or
an aromatase inhibitor) for adjuvant treatment of
patients with HR-positive, HER2-negative, node-positive,
early breast cancer at high risk of recurrence
and a Ki-67 score ≥20%.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
® Vol. 61 (1575) July 1, 2019
Table 1. Some Hormones for Menopausal Vasomotor Symptoms
Drug Some ...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
.
All rights reserved. ©2022. www.fdbhealth.com/policies/drug-pricing-policy.
17. The minimum interval between ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Platelet-Derived Growth Factor for Diabetic Ulcers
The Medical Letter on Drugs and Therapeutics • Jul 17, 1998 (Issue 1031)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Becaplermin (be kap' ler min; Regranex - Ortho-McNeil), a 0.01% topical gel formulation of recombinant human platelet-derived growth factor (rhPDGF), was recently approved by the FDA for adjunctive treatment of diabetic ulcers of the lower extremities that extend subcutaneously or beyond and have an adequate blood supply. Endogenous platelet-derived growth factor increases proliferation of cells that repair wounds and form granulation tissue.
In Brief: Propofol Revisited
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011 (Issue 1375)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1375)
October 17, 2011 ...
A reader has asked us to review the use of propofol (Diprivan, and others) as a sedative agent for brief procedures, such as colonoscopy.First marketed more than 20 years ago,1 propofol has a rapid onset of action (patients usually lose consciousness in less then one minute) and a short duration of action with a rapid recovery (3-5 minutes) that makes it highly suitable for brief ambulatory procedures. Propofol is now the most commonly used parenteral anesthetic in the US.2 The main problems with its use have been pain on injection and bacterial contamination, both related to its lipid...
In Brief: Calcium and Vitamin D to Prevent Osteoporotic Fractures
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1393)
June 25, 2012 ...
The US Preventive Services Task Force (USPSTF) has issued a Draft Recommendation Statement saying, in effect, that community-dwelling women and men should not take calcium and vitamin D supplements for primary prevention of osteoporotic fractures because the evidence that they are helpful is insufficient and they increase the risk of kidney stones. The Medical Letter has said previously that there is no evidence that patients with an adequate intake of calcium (1000-1200 mg/day) and vitamin D (600-800 IU/day) will benefit from taking supplements.11. Drugs for postmenopausal osteoporosis. Treat...
In Brief: Two New Seasonal Influenza Vaccines
The Medical Letter on Drugs and Therapeutics • Feb 04, 2013 (Issue 1409)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1409)
February 4, 2013 ...
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old (Flublok). Unlike other available influenza vaccines, neither vaccine is produced in eggs, removing any concern regarding use in egg-allergic patients. Avoiding the use of eggs should allow for faster production of these 2 new vaccines, which could be especially beneficial during a pandemic.Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is...
Treatment of COVID-19 in High-Risk Outpatients (online only)
The Medical Letter on Drugs and Therapeutics • Jan 28, 2022 (Issue 1643)
-Pugh C), patients taking strong CYP3A inducers4 or high-risk, highly CYP3A-dependent drugs (e.g ...
View the Treatment of COVID-19 in High-Risk Outpatients Chart
